Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Depreciation & Amortization (CF) (2016 - 2025)

Neurocrine Biosciences (NBIX) has disclosed Depreciation & Amortization (CF) for 15 consecutive years, with $6.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Depreciation & Amortization (CF) rose 3.23% year-over-year to $6.4 million, compared with a TTM value of $26.0 million through Dec 2025, up 10.64%, and an annual FY2025 reading of $26.0 million, up 10.64% over the prior year.
  • Depreciation & Amortization (CF) was $6.4 million for Q4 2025 at Neurocrine Biosciences, down from $6.7 million in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $6.7 million in Q3 2025 and bottomed at $2.5 million in Q1 2021.
  • Average Depreciation & Amortization (CF) over 4 years is $5.4 million, with a median of $5.6 million recorded in 2024.
  • The sharpest move saw Depreciation & Amortization (CF) skyrocketed 52.38% in 2024, then decreased 1.56% in 2025.
  • Year by year, Depreciation & Amortization (CF) stood at $2.5 million in 2021, then soared by 96.0% to $4.9 million in 2023, then grew by 26.53% to $6.2 million in 2024, then grew by 3.23% to $6.4 million in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for NBIX at $6.4 million in Q4 2025, $6.7 million in Q3 2025, and $6.3 million in Q2 2025.